RALTITREXED for Hepatic cancer: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 14 adverse event reports in the FDA FAERS database where RALTITREXED was used for Hepatic cancer.
Most Reported Side Effects for RALTITREXED
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 82 | 19.2% | 22 | 27 |
| Myelosuppression | 77 | 18.0% | 0 | 48 |
| Anaemia | 49 | 11.5% | 4 | 14 |
| Neutropenia | 48 | 11.2% | 4 | 20 |
| Vomiting | 46 | 10.8% | 9 | 17 |
| Nausea | 45 | 10.5% | 9 | 13 |
| Disease progression | 40 | 9.4% | 12 | 11 |
| Fatigue | 38 | 8.9% | 1 | 13 |
| Asthenia | 33 | 7.7% | 4 | 12 |
| Hepatic function abnormal | 26 | 6.1% | 1 | 8 |
| Off label use | 25 | 5.8% | 1 | 6 |
| Bone marrow failure | 23 | 5.4% | 0 | 8 |
| Decreased appetite | 21 | 4.9% | 0 | 5 |
| Thrombocytopenia | 21 | 4.9% | 1 | 2 |
| Rash | 20 | 4.7% | 0 | 9 |
Other Indications for RALTITREXED
Colon cancer (63)
Colorectal cancer metastatic (47)
Adenocarcinoma of colon (35)
Rectal cancer (31)
Colorectal cancer (28)
Rectal adenocarcinoma (18)
Metastases to liver (17)
Adenocarcinoma gastric (13)
Chemotherapy (13)
Metastatic gastric cancer (12)
Other Drugs Used for Hepatic cancer
SORAFENIB (1,167)
LENVATINIB (1,017)
BEVACIZUMAB (532)
CABOZANTINIB S-MALATE (508)
ATEZOLIZUMAB (459)
TISLELIZUMAB (315)
CAPECITABINE (267)
NIVOLUMAB (262)
REGORAFENIB (252)
OXALIPLATIN (188)